Grafton Optical is promoting its exclusive distribution in the UK of E-Eye. The product has been designed for the treatment of dry eye due to meibomian gland dysfunction (MGD), and is described by the company as the “first and only medical device in the world using intense regulated pulsed light (IRPL).”
Grafton Optical explained to OT that the E-Eye uses the IRPL technology to regenerate the function of the meibomian glands and improve the quality of their secretions.
“This new type of polychromatic pulsed light produces perfected calibrated and homogenously sequenced light pulses which stimulate the parasympathetic nerves. This in turn encourages the meibomian glands to restore their natural lipid flow, reducing tear evaporation and preventing the eyes from becoming dry,” the company added.
Managing director of Grafton Optical, Brian Bowles, told OT: “We have seen huge interest and success with the E-Eye since its launch in the UK last year. It offers huge benefits not only to patients suffering from MGD-related dry eye but also to practices wishing to increase their income.”
The E-Eye is made in France by ESW Vision, the world’s largest intense pulsed light device manufacturer.
To arrange a demonstration of the E-Eye in the practice, email Grafton Optical or telephone 01923 233980.